Michael F. MacLean - 06 Aug 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Financial Officer
Signature: /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol: RNA
Transactions as of: 06 Aug 2025
Transactions value $: -$1,320,844
Form type: 4
Filing time: 15 Aug 2025, 16:09:38
Previous filing: 28 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MacLean Michael F	Chief Financial Officer	C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	15 Aug 2025	0001383731

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Sale	-$1.32M	-30.9K	-31.96%	$42.73	65.8K	06 Aug 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on July 8, 2024.
F2	This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $43.92. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on July 8, 2024.

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $43.92. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.